Publications

1. Conditional inclusion procedure for medicinal products

   This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

   Publication | 29-09-2023

2. Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

   The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate teduglutide (Revestive®) ...

   Report | 21-09-2023

3. Package advice for the lock procedure medicinal product zanubrutinib (Brukinsa®) for the treatment of chronic lymphocytic leukaemia (CLL)

   The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

   Report | 31-08-2023

4. GVS advice fenfluramine (Fintepla®) for the treatment of epileptic seizures in Dravet Syndrome or Lennox-Gastaut Syndrome

   The National Health Care Institute has assessed whether fenfluramine (Fintepla®) can be included in the Medicine Reimbursement ...

   Report | 31-08-2023

5. GVS advice midazolam (Midazolam Xiromed®) for the treatment of epilepsy

   The National Health Care Institute has assessed whether oromucosal administration of midazolam (Midazolam Xiromed®) can be ...

   Report | 22-08-2023

6. GVS advice for tirzepatide (Mounjaro®) for the treatment of adults with type 2 diabetes mellitus without a very high risk of cardiovascular disease

   The National Health Care Institute has assessed whether tirzepatide (Mounjaro®) can be included in the Medicine Reimbursement ...

   Report | 14-08-2023

7. Advice - Extension of conditional inclusion procedure for ataluren (Translarna®)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the conditional ...

   Report | 31-07-2023

8. GVS advice glucagon (Ogluo®) for the treatment of severe hypoglycaemia in adults and children aged 2 years and older

   The National Health Care Institute assessed whether the administration of subcutaneous glucagon (administration under the skin) ...

   Report | 28-07-2023

9. Package advice for lock procedure medicinal product darolutamide (Nubeqa®) for the treatment of metastatic prostate cancer

   The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...

   Report | 28-07-2023

10. Package advice eptinezumab (Vyepti®) for the treatment of migraine

    The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

    Report | 28-07-2023